Lindbrook Capital, LLC Arcutis Biotherapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.06 Billion
- Q2 2024
A detailed history of Lindbrook Capital, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 357 shares of ARQT stock, worth $3,409. This represents 0.0% of its overall portfolio holdings.
Number of Shares
357
Previous 482
25.93%
Holding current value
$3,409
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
127MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$111 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$95.5 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$93.7 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$83.9 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$82.3 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $575M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...